임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 16-03-14 01:27
논문번호 124
논문제목(영문) Percutaneous coronary intervention with drug-eluting stent implantation vs. coronary artery bypass grafting for multivessel coronary artery disease in metabolic syndrome patients with acute myocardial infarction.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 교신저자
주저자명 Ahmed K
교신저자명 Jeong MH
공동저자명 Ahmed K, Jeong MH, Chakraborty R, Hong YJ, Sim DS, Hwang SH, Lee MG, Park KH, Kim JH, Ahn Y, Cho MC, Kim CJ, Kim YJ, Park JC, Kang JC;
게제년월일 2011-11-11
ISSN 1346-9843
Impact Factor 3.940
학술지명 Circulation journal
서지사항 0집 / 76권 / 3호,   페이지(721 - 728)
요약초록문
(Abstract) 입력		 Abstract: BACKGROUND: Coronary artery bypass grafting (CABG) has been the treatment of choice for management of multivessel coronary artery disease, but percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is increasingly being preferred. The aim of the present study was to compare outcomes of PCI with DES implantation (PCI-DES) and CABG for treating multivessel disease in metabolic syndrome patients with acute myocardial infarction (AMI).
METHODS AND RESULTS: A total of 1,839 consecutive metabolic syndrome patients with AMI who underwent PCI-DES (n=1,715) and CABG (n=124) for treatment of multivessel disease were selected from Korea Acute Myocardial Infarction Registry from November 2005 through December 2006. Primary endpoint was 12-month all-cause mortality. The mortality rate at 12 months was significantly lower in the PCI-DES group (4.8% vs. 12.2% in CABG, P=0.014) on univariate analysis. According to a Cox model, 12-month mortality was similar between the 2 groups (P=0.603), which remained the same despite propensity score adjustment (P=0.485). Rate of repeat revascularization was significantly higher in the PCI-DES group compared to the CABG group (P<0.001). At 12 months, major adverse cardiovascular and cerebrovascular event (MACCE)-free survival was higher in ST-elevation MI (STEMI) patients in the CABG group.
CONCLUSIONS: PCI-DES had an equivalent 12-month mortality risk to CABG for the treatment of multivessel disease in metabolic syndrome patients with AMI. CABG is more favorable for STEMI patients in terms of MACCE.
파일  C124.+Circ+J.+2012;76(3)721-728..pdf (825.1K) DATE : 2021-05-26 09:38:48